Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
    • WoS Reviewer Recognition Service
  • Alerts
  • Subscriptions

N-acetylcysteine (NAC) in the complex treatment of COVID-associated pneumonia

Viliya Gaynitdinova, Sergey Avdeev, Zamira Merzhoeva, Galia Nuralieva
European Respiratory Journal 2021 58: PA3669; DOI: 10.1183/13993003.congress-2021.PA3669
Viliya Gaynitdinova
1Dept. of Pulmonology, Sechenov University, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ivv_08@mail.ru
Sergey Avdeev
1Dept. of Pulmonology, Sechenov University, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zamira Merzhoeva
1Dept. of Pulmonology, Sechenov University, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Galia Nuralieva
1Dept. of Pulmonology, Sechenov University, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: The pharmacological activity of NAC and its potential effects in suppressing the progression of COVID-19 make it a promising therapeutic agent in COVID-19.

Aims and objectives: To evaluate the efficacy of NAC in the complex treatment of COVID-associated pneumonia.

Methods: In this open-label study 46 patients with COVID-associated moderately severe pneumonia (age was 57,9±12,73 years, disease duration before admission 7,3±1,64 days, body temperature at admission 37,5±0,43 C, lung damage on quantitative chest CT 44±6,46%, oxygenation index (SpO2/FiO2) – 253±19),were randomized into 2 groups: Group 1 (n=22) received standard treatment for COVID-19; Group 2 (n=24) in addition received NAC 1200-1500 mg/day intravenously. Clinical laboratory examination and chest CT scan were performed on the 1st and 10th days of observation.

Results: After the treatment we observed significantly higher increase in blood oxygen saturation (SpO2) and SpO2/FiO2 in NAC group compared to control group: 97(96;98)% vs. 96(96;97)% (p=0,02) and 459 (399;476) vs. 401(331;451) (p=0,03), respectively. The delta of growth in SpO2/FiO2 was significantly higher in NAC group: 175±54,3 & 144±54,4 (p=0,02). The delta of receding percent of lung damage in CT scan was 14±3,94% in NAC group vs. 6,9±2,56% in the control group (p<0,001). We observed a steeper decrease of C-reactive protein levels in NAC group over 10 days of treatment: 90±10,2% vs. 82±13,9% (p=0,03). The addition of NAC to standard therapy was associated with reduced duration of hospital stay (p<0,001).

Conclusions: The findings of the study demonstrate the effectiveness of including NAC in the complex treatment of COVID-associated pneumonia of medium severity.

  • Pneumonia
  • Treatments
  • Viruses

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3669.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
N-acetylcysteine (NAC) in the complex treatment of COVID-associated pneumonia
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
N-acetylcysteine (NAC) in the complex treatment of COVID-associated pneumonia
Viliya Gaynitdinova, Sergey Avdeev, Zamira Merzhoeva, Galia Nuralieva
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3669; DOI: 10.1183/13993003.congress-2021.PA3669

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
N-acetylcysteine (NAC) in the complex treatment of COVID-associated pneumonia
Viliya Gaynitdinova, Sergey Avdeev, Zamira Merzhoeva, Galia Nuralieva
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3669; DOI: 10.1183/13993003.congress-2021.PA3669
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • RCT Abstract - Safety and efficacy of idrevloride in people with primary ciliary dyskinesia: a double-blind, randomized, placebo-controlled crossover trial (CLEAN-PCD)
  • Clinical management of pneumonia versus recommendations of the separ guidelines.
  • Altered sphingolipid metabolism in community acquired pneumonia
Show more Respiratory infections and bronchiectasis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society